Blocking an Endocannabinoid-Degrading Enzyme Relieved Migraine Pain in Mice Without Tolerance

The MAGL inhibitor ABD-1970 blocked cephalic allodynia in both acute and chronic nitroglycerin-induced migraine models. Repeated daily administration for 5 days did not produce tolerance. MAGL and CB1 receptor mRNA were highly expressed in both the trigeminal ganglia and trigeminal nucleus caudalis, key pain-processing regions for headache.

C57BL6/J male and female mice received nitroglycerin (a human migraine trigger) acutely or every other day for 9 days to model chronic migraine. Periorbital allodynia was measured by von Frey hair stimulation. ABD-1970 was tested as a single dose in acute and chronic models and daily for 5 days to assess tolerance. In situ hybridization mapped MAGL and CB1 expression in trigeminal pain circuits.

Migraine affects over 1 billion people worldwide and current treatments often lose effectiveness or have significant side effects. Enhancing the endocannabinoid system by blocking the enzyme that breaks down natural cannabinoids offers a fundamentally different approach that may avoid the tolerance issues seen with direct cannabinoid receptor activation.

Direct cannabis use for migraine carries tolerance risk and side effects. MAGL inhibitors work differently by boosting the body's own endocannabinoids at the exact times and places they are naturally released. The lack of tolerance in this study is particularly encouraging compared to direct CB1 agonists.

Mouse migraine models rely on nitroglycerin-induced pain, which may not capture all aspects of human migraine. Five days of dosing is very short to assess long-term tolerance. The specific inhibitor (ABD-1970) has not been tested in humans.